How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
62
RHHBF Quote, Financials, Valuation and Earnings
Last price:
$441.17
Seasonality move
:
-1.44%
Day range:
$440.00 - $440.00
52-week range:
$288.90 - $470.38
Dividend yield:
2.5%
P/E ratio:
41.11x
P/S ratio:
4.76x
P/B ratio:
7.17x
Volume:
--
Avg. volume:
19
1-year change:
28.21%
Market cap:
$350.1B
Revenue:
$74.1B
EPS (TTM):
$10.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RHHBF
Roche Holding AG
|
$19.8B | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$1.5M | -$0.22 | 18.61% | -6.92% | $9.21 |
|
GALDY
Galderma Group AG
|
-- | -- | -- | -- | -- |
|
NVS
Novartis AG
|
$14.1B | $2.00 | 4.19% | 14.01% | $140.00 |
|
ONC
BeOne Medicines Ltd.
|
$1.5B | $1.44 | 25.24% | 4402.9% | $404.19 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RHHBF
Roche Holding AG
|
$440.00 | -- | $350.1B | 41.11x | $11.00 | 2.5% | 4.76x |
|
ACIU
AC Immune SA
|
$3.27 | $9.21 | $329M | -- | $0.00 | 0% | 63.77x |
|
GALDY
Galderma Group AG
|
$37.73 | -- | $44.3B | 130.29x | $0.03 | 0.04% | 9.57x |
|
NVS
Novartis AG
|
$151.04 | $140.00 | $289.8B | 20.60x | $3.99 | 2.64% | 5.47x |
|
ONC
BeOne Medicines Ltd.
|
$345.00 | $404.19 | $38.2B | 663.72x | $0.00 | 0% | 7.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RHHBF
Roche Holding AG
|
53.53% | -0.728 | -- | 0.88x |
|
ACIU
AC Immune SA
|
6.95% | 3.733 | 2.01% | 1.10x |
|
GALDY
Galderma Group AG
|
26.02% | 1.432 | -- | 0.80x |
|
NVS
Novartis AG
|
41.94% | -0.357 | 12.99% | 0.58x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | -0.304 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RHHBF
Roche Holding AG
|
-- | -- | 14.32% | 28.65% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
GALDY
Galderma Group AG
|
-- | -- | 3.62% | 4.9% | -- | -- |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Roche Holding AG vs. Competitors
-
Which has Higher Returns RHHBF or ACIU?
AC Immune SA has a net margin of -- compared to Roche Holding AG's net margin of -1688.87%. Roche Holding AG's return on equity of 28.65% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital RHHBFRoche Holding AG-- -- $82.8B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About RHHBF or ACIU?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of -89.09%. On the other hand AC Immune SA has an analysts' consensus of $9.21 which suggests that it could grow by 181.86%. Given that AC Immune SA has higher upside potential than Roche Holding AG, analysts believe AC Immune SA is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBFRoche Holding AG0 0 0 ACIUAC Immune SA4 0 0 -
Is RHHBF or ACIU More Risky?
Roche Holding AG has a beta of 0.286, which suggesting that the stock is 71.428% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.038%.
-
Which is a Better Dividend Stock RHHBF or ACIU?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.5%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 61.57% of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBF or ACIU?
Roche Holding AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Roche Holding AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Roche Holding AG's price-to-earnings ratio is 41.11x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.76x versus 63.77x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBFRoche Holding AG4.76x 41.11x -- -- ACIUAC Immune SA63.77x -- $1.2M -$19.8M
-
Which has Higher Returns RHHBF or GALDY?
Galderma Group AG has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 28.65% beat Galderma Group AG's return on equity of 4.9%.
Company Gross Margin Earnings Per Share Invested Capital RHHBFRoche Holding AG-- -- $82.8B GALDYGalderma Group AG-- -- $10.4B -
What do Analysts Say About RHHBF or GALDY?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of -89.09%. On the other hand Galderma Group AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Roche Holding AG has higher upside potential than Galderma Group AG, analysts believe Roche Holding AG is more attractive than Galderma Group AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBFRoche Holding AG0 0 0 GALDYGalderma Group AG0 0 0 -
Is RHHBF or GALDY More Risky?
Roche Holding AG has a beta of 0.286, which suggesting that the stock is 71.428% less volatile than S&P 500. In comparison Galderma Group AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RHHBF or GALDY?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.5%. Galderma Group AG offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. Roche Holding AG pays 61.57% of its earnings as a dividend. Galderma Group AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBF or GALDY?
Roche Holding AG quarterly revenues are --, which are smaller than Galderma Group AG quarterly revenues of --. Roche Holding AG's net income of -- is lower than Galderma Group AG's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 41.11x while Galderma Group AG's PE ratio is 130.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.76x versus 9.57x for Galderma Group AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBFRoche Holding AG4.76x 41.11x -- -- GALDYGalderma Group AG9.57x 130.29x -- --
-
Which has Higher Returns RHHBF or NVS?
Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 28.26%. Roche Holding AG's return on equity of 28.65% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital RHHBFRoche Holding AG-- -- $82.8B NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About RHHBF or NVS?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of -89.09%. On the other hand Novartis AG has an analysts' consensus of $140.00 which suggests that it could fall by -7.31%. Given that Roche Holding AG has more downside risk than Novartis AG, analysts believe Novartis AG is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBFRoche Holding AG0 0 0 NVSNovartis AG1 5 2 -
Is RHHBF or NVS More Risky?
Roche Holding AG has a beta of 0.286, which suggesting that the stock is 71.428% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.176%.
-
Which is a Better Dividend Stock RHHBF or NVS?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.5%. Novartis AG offers a yield of 2.64% to investors and pays a quarterly dividend of $3.99 per share. Roche Holding AG pays 61.57% of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBF or NVS?
Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.9B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $3.9B. Notably, Roche Holding AG's price-to-earnings ratio is 41.11x while Novartis AG's PE ratio is 20.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.76x versus 5.47x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBFRoche Holding AG4.76x 41.11x -- -- NVSNovartis AG5.47x 20.60x $13.9B $3.9B
-
Which has Higher Returns RHHBF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Roche Holding AG's net margin of 8.84%. Roche Holding AG's return on equity of 28.65% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital RHHBFRoche Holding AG-- -- $82.8B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About RHHBF or ONC?
Roche Holding AG has a consensus price target of --, signalling downside risk potential of -89.09%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $404.19 which suggests that it could grow by 17.16%. Given that BeOne Medicines Ltd. has higher upside potential than Roche Holding AG, analysts believe BeOne Medicines Ltd. is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBFRoche Holding AG0 0 0 ONCBeOne Medicines Ltd.19 0 1 -
Is RHHBF or ONC More Risky?
Roche Holding AG has a beta of 0.286, which suggesting that the stock is 71.428% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.518, suggesting its less volatile than the S&P 500 by 48.23%.
-
Which is a Better Dividend Stock RHHBF or ONC?
Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.5%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 61.57% of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBF or ONC?
Roche Holding AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Roche Holding AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Roche Holding AG's price-to-earnings ratio is 41.11x while BeOne Medicines Ltd.'s PE ratio is 663.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.76x versus 7.71x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBFRoche Holding AG4.76x 41.11x -- -- ONCBeOne Medicines Ltd.7.71x 663.72x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 43x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 43x
Alerts
Sell
49
HYMC alert for Feb 3
Hycroft Mining Holding Corp. [HYMC] is up 14.6% over the past day.
Buy
67
FBRX alert for Feb 3
Forte Biosciences, Inc. [FBRX] is up 0.03% over the past day.
Buy
72
BNR alert for Feb 3
Burning Rock Biotech Ltd. [BNR] is down 15.03% over the past day.
